Pentixapharm Holding AG Completes IPO in the Prime Standard of the Frankfurt Stock Exchange - See Article

Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism - See Article

ELSA underwrites start-up financing for CellSense Technology GmbH (German press release) - PDF

Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer - PDF

Myelo Therapeutics selected to receive Multi-Million Euro Grant from the European Defense Fund for the Development of Medical Countermeasures - PDF

Eckert & Ziegler Strahlen- und Medizintechnik AG Acquires Direct Majority Stake in Drug Developer Pentixapharm - See Article

DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms - PDF

Pentixapharm Secures € 15 Million Series A Financing to Develop CXCR4-Targeted Theranostics - See Article

Myelo Therapeutics Awarded NIH-NIAID Contract Valued up to $6 Million over 3 Years for Development of Myelo001 as Treatment for Acute Radiation Syndrome - PDF

FDA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome - PDF

DCprime and Glycotope announce licensing agreement and collaboration - PDF

Myelo Therapeutics conducts successful Pre-IND meeting with U.S. Food and Drug Administration (FDA) for Myelo001 and completes new financing round - PDF